Cardiometabolic risk factors during risperidone treatment in children with intellectual disability

บทคัดย่อ

Objective The aim of this study was to investigate the cardiometabolic risk factors during risperidone treatment in children with intellectual disability (ID).

Materials and methods This observation analytic study with cross-sectional design was conducted at Rajanukul Institute. All 111 patients, medically healthy 7-17 year old children with ID treated with risperidone were recruited. Age and sex-adjusted weight percentiles/z-scores change and metabolic parameters were collected. Correlation between inappropriate weight gain and laboratory components of cardiometabolic risk factors was analyzed.

Results Among 111 children with intellectual disability, 92 participants were male. Mean age at enrollment was 10.6 years. The average dose of risperidone treatment was 0.04 mg/day for an average duration of 2.9 years. Forty percents of participants showed abnormally high levels of low density lipo-protein cholesterol. Four percents of participants showed abnormally high glucose levels. Twenty- sixth percent of participants showed developmentally-inappropriate weight gain. Compared to participants with normal blood result, those with dyslipidemia were more likely to have inappropriate weight gain. The odds of having inappropriate weight gain in participants who have at least one laboratory metabolic abnormality was 4.7 times for the group of normal blood test and the odds of having inappropriate weight gain in participants who have two or more laboratory metabolic abnormalities was 5.5 times.

Conclusion In children with intellectual disability who treated with risperidone for an average dose of 0.04 mg/day, an average duration of 2.9 years.The prevalence rate of dyslipidemia was 40 percents and the prevalence rate of developmentally-inappropriate weight gain was 26 percents. A number of laboratory components of cardiometabolic risk factors correlate well with inappropriate weight gain.